{
    "ticker": "ANVS",
    "name": "Annovis Bio, Inc.",
    "description": "Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for neurodegenerative diseases. Founded in 2017 and headquartered in Berwyn, Pennsylvania, Annovis aims to address significant unmet medical needs in the treatment of Alzheimer's disease, Parkinson's disease, and other related disorders. The company's proprietary technology platform is based on the research of Dr. Maria L. Maccecchini, who has dedicated her career to discovering new treatments for these debilitating conditions. Annovis is advancing its lead drug candidate, ANVS401, which has shown potential to halt and even reverse the progression of neurodegenerative diseases by targeting the underlying causes of neuronal cell death. The company is committed to improving the quality of life for patients and their families affected by these challenging disorders. With a strong pipeline and rigorous clinical trials, Annovis Bio is poised to make significant contributions to the field of neuroscience and therapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Berwyn, Pennsylvania, USA",
    "founded": "2017",
    "website": "https://www.annovisbio.com",
    "ceo": "Maria L. Maccecchini",
    "social_media": {
        "twitter": "https://twitter.com/annovisbio",
        "linkedin": "https://www.linkedin.com/company/annovis-bio/"
    },
    "investor_relations": "https://www.annovisbio.com/investors",
    "key_executives": [
        {
            "name": "Maria L. Maccecchini",
            "position": "CEO"
        },
        {
            "name": "Samantha S. L. Burkett",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ANVS401"
            ]
        }
    ],
    "seo": {
        "meta_title": "Annovis Bio, Inc. | Innovating Neurodegenerative Disease Therapies",
        "meta_description": "Annovis Bio, Inc. is dedicated to developing therapies for neurodegenerative diseases, focusing on Alzheimer\u2019s and Parkinson\u2019s. Explore our innovative pipeline and mission.",
        "keywords": [
            "Annovis Bio",
            "Neurodegenerative Diseases",
            "Alzheimer's Disease",
            "Parkinson's Disease",
            "ANVS401"
        ]
    },
    "faq": [
        {
            "question": "What is Annovis Bio known for?",
            "answer": "Annovis Bio is known for its innovative therapies targeting neurodegenerative diseases, particularly Alzheimer's and Parkinson's."
        },
        {
            "question": "Who is the CEO of Annovis Bio?",
            "answer": "Maria L. Maccecchini is the CEO of Annovis Bio, Inc."
        },
        {
            "question": "Where is Annovis Bio headquartered?",
            "answer": "Annovis Bio is headquartered in Berwyn, Pennsylvania, USA."
        },
        {
            "question": "What is Annovis Bio's lead product?",
            "answer": "Annovis Bio's lead product is ANVS401, aimed at treating neurodegenerative diseases."
        },
        {
            "question": "When was Annovis Bio founded?",
            "answer": "Annovis Bio was founded in 2017."
        }
    ],
    "competitors": [
        "ADMS",
        "ACAD",
        "PRTA",
        "BIIB"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}